Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of ...

Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Following the game-changing success of Spinraza, a molecular-based therapy that was crucial in the treatment of SMA (Spinal Muscular Atrophy), which used to be one of the leading genetic killers of ...

WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, ...

Throughout his career, he has held pivotal research and development roles, contributing significantly to the creation of ...

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

AIA Group Ltd raised its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 10.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,411 shares of the biotechnology company’s stock ...

Evrysdi is the third treatment approved for SMA, an ultra-rare muscle wasting disease that can begin in early childhood, after Biogen’s Spinraza (nusinersen) and Novartis’ Zolgensma ...